

- **PREGNANCY** Manufacturer advises avoid.
- **BREAST FEEDING** Avoid—present in milk in *animal* studies.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment (risk of increased exposure).
Dose adjustments Manufacturer advises dose reduction of 50% in moderate to severe impairment.
- **DIRECTIONS FOR ADMINISTRATION** Orodispersible tablets should be placed on the tongue, allowed to disperse and swallowed, or may be swallowed whole with a glass of water. Alternatively, tablets can be dispersed in a small amount of water and administered by an oral syringe or nasogastric tube.
- **PATIENT AND CARER ADVICE** Counselling on administration of orodispersible tablet advised.
- **PROFESSION SPECIFIC INFORMATION**
Dental practitioners' formulary
Lansoprazole capsules may be prescribed.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder

Gastro-resistant capsule

CAUTIONARY AND ADVISORY LABELS 5, 22, 25

▶ **Lansoprazole (Non-proprietary)**Lansoprazole 15 mg Lansoprazole 15mg gastro-resistant capsules | 28 capsule [PoM](#) £12.93 DT = £0.97Lansoprazole 30 mg Lansoprazole 30mg gastro-resistant capsules | 28 capsule [PoM](#) £23.63 DT = £1.27**Orodispersible tablet**

CAUTIONARY AND ADVISORY LABELS 5, 22

EXCIPIENTS: May contain Aspartame

▶ **Lansoprazole (Non-proprietary)**Lansoprazole 15 mg Lansoprazole 15mg orodispersible tablets | 28 tablet [PoM](#) £3.05 DT = £2.98Lansoprazole 30 mg Lansoprazole 30mg orodispersible tablets | 28 tablet [PoM](#) £4.95 DT = £4.62▶ **Zoton FasTab** (Pfizer Ltd)Lansoprazole 15 mg Zoton FasTab 15mg | 28 tablet [PoM](#) £2.99 DT = £2.98Lansoprazole 30 mg Zoton FasTab 30mg | 28 tablet [PoM](#) £5.50 DT = £4.62

82

26-Nov-2019

Omeprazole**INDICATIONS AND DOSE*****Helicobacter pylori* eradication [in combination with other drugs (see *Helicobacter pylori* infection p. 89)]**

▶ BY MOUTH

- ▶ Adult: 20–40 mg twice daily for 7 days for first- and second-line eradication therapy; 10 days for third-line eradication therapy

Benign gastric ulceration

▶ BY MOUTH

- ▶ Adult: 20 mg once daily for 8 weeks, increased if necessary to 40 mg once daily, in severe or recurrent cases

Duodenal ulceration

▶ BY MOUTH

- ▶ Adult: 20 mg once daily for 4 weeks, increased if necessary to 40 mg once daily, in severe or recurrent cases

Prevention of relapse in gastric ulcer

▶ BY MOUTH

- ▶ Adult: 20 mg once daily, increased if necessary to 40 mg once daily

Prevention of relapse in duodenal ulcer

▶ BY MOUTH

- ▶ Adult: 20 mg once daily, dose may range between 10–40 mg daily

NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer | NSAID-associated gastroduodenal erosions

▶ BY MOUTH

- ▶ Adult: 20 mg once daily for 4 weeks, continued for a further 4 weeks if not fully healed

Prophylaxis in patients with a history of NSAID-associated duodenal ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastric ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastroduodenal lesions who require continued NSAID treatment**Prophylaxis in patients with a history of NSAID-associated gastroduodenal lesions who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated dyspeptic symptoms who require continued NSAID treatment**

▶ BY MOUTH

- ▶ Adult: 20 mg once daily

Zollinger–Ellison syndrome

▶ BY MOUTH

- ▶ Adult: Initially 60 mg once daily; usual dose 20–120 mg daily, total daily doses greater than 80 mg should be given in 2 divided doses

▶ BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION

- ▶ Adult: Initially 60 mg once daily, adjusted according to response, total daily doses greater than 60 mg should be given in 2 divided doses, injection to be given over 5 minutes, infusion to be given over 20–30 minutes

Gastro-oesophageal reflux disease

▶ BY MOUTH

- ▶ Adult: 20 mg once daily for 4 or 8 weeks

Severe oesophagitis

▶ BY MOUTH

- ▶ Adult: 40 mg once daily for 8 weeks, continue as maintenance treatment if appropriate

Severe oesophagitis, refractory to initial treatment

▶ BY MOUTH

- ▶ Adult: 40 mg twice daily

Acid reflux disease (long-term management)

▶ BY MOUTH

- ▶ Adult: 10 mg once daily, increased to 20 mg once daily, dose only increased if symptoms return

Functional dyspepsia

▶ BY MOUTH

- ▶ Adult: 10 mg once daily for 4 weeks

Uninvestigated dyspepsia

▶ BY MOUTH

- ▶ Adult: 20 mg once daily for 4 weeks

Treatment and prevention of benign gastric ulcers | Treatment and prevention of duodenal ulcers | Treatment and prevention of NSAID-associated ulcers | Treatment and prevention of gastro-oesophageal reflux disease**Treatment and prevention of NSAID-associated ulcers | Treatment and prevention of gastro-oesophageal reflux disease**

▶ BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION

- ▶ Adult: 40 mg once daily until oral administration possible, injection to be given over 5 minutes, infusion to be given over 20–30 minutes

Major peptic ulcer bleeding (following endoscopic treatment)

▶ INITIALLY BY INTRAVENOUS INFUSION

- ▶ Adult: Initially 80 mg, to be given over 40–60 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, subsequent dose then changed to oral therapy

UNLICENSED USE

- ▶ With oral use [EvGr](#) Duration of treatment for gastro-oesophageal reflux disease differs from product literature and adheres to national guidelines. [⚡](#) See Gastro-oesophageal reflux disease p. 88 for further information.